Effect of High-Dose Intravenous N-acetylcysteine on the Concentration of Plasma Sulfur-Containing Amino Acids

Sae-Yong Hong, M.D., Hyo-Wook Gil, M.D., Jong-Oh Yang, M.D., Eun-Young Lee, M.D., Hyung-Kee Kim, M.D.,2 Soo-Hyun Kim, Ph.D.,3 Young-Ho Chung, Ph.D.3, Eun-Mi Lee3, and Soo-Kyung Hwang3

Departments of Internal Medicine, Clinical Pharmacology2 and Soonchunhyang University Chunan Hospital, Chunan, Korea; Proteome Analysis Team, Korea Basic Science Institute3, Daejeon, Korea

Background : The purpose of this study was to determine the adequate loading and maintenance doses of N-acetylcysteine (NAC) for patients suffering from acute ROS-induced injury.

Methods : Concentrations of extra cellular NAC, cysteine (Cys), cystine (Cyst2), and methionine (Met) were measured in vitro, at which more than 50% of the intracellular ROS raised by paraquat were suppressed using Swiss 3T3 fibroblasts. An in vivo pharmacokinetic study followed on a healthy subject to determine the proper loading and maintenance doses of reduced NAC following intravenous administration of 25 mg/kg NAC.

Results : In vivo, NAC suppressed ROS in a dose dependant manner. 10 mM of NAC suppressed about 50% of ROS, and was comparable to 10 μM of Cys and Met and 400 μM of Cys2.

In vitro, the elimination of half life was achieved at 2.88±1.14 h for NAC and at 3.68±1.84 h for total NAC. The body clearances were 1.23±0.77 L h⁻¹ kg⁻¹ and 0.56±0.27 L h⁻¹ kg⁻¹ and the volumes of distribution were 3.07±0.10 L kg⁻¹ and 3.00±0.11 L kg⁻¹, respectively.

The loading and maintenance NAC doses used to reach the target concentration of 10 mM, were 5010 mg kg⁻¹ and 2250 mg min⁻¹ kg⁻¹, respectively.

Conclusion : NAC provides an antioxidant effect on ROS produced by paraquat in vivo. However, in vitro, our results showed that the intravenous NAC dose could not be estimated from NAC plasma concentration or its metabolites.

Key Words : Acetylcysteine, Reactive oxygen species, Amino acids, Sulfur

INTRODUCTION

Glutathione (GSH) is a cysteine-containing tripeptide (glutamylcysteinylglycine) that plays a wide variety of physiological roles, including regulation of signal transduction and intracellular defense against oxidative stress1. GSH deficiency and oxidative stress have been associated with a series of debilitating diseases such as Parkinson’s disease2,3, Human immunodeficiency virus (HIV) infection4,5, ischemic heart6,7, and acute paraquat intoxication8,9.

Among them, the clinical course of acute paraquat intoxication is one of the most critical because it progresses fast and most patients die within few days. An early observation by Bus et al.10 was that depletion of GSH enhanced paraquat toxicity. Furthermore, the evidence that GSH peroxidase plays a key role in protecting animals against paraquat toxicity has been
shown in recent studies on transgenic mice. However, the antioxidant effectiveness of exogenous GSH has been hindered by its rapid hydrolysis in the circulation and its inability to cross cell membranes. Synthesis of GSH occurs intracellularly from its constituent amino acids, via the reactions of the gamma glutamyl cycle. In this setting, the availability of cysteine (Cys) is considered to be the rate limiting step of GSH synthesis, and the control point in GSH synthesis appears to be the gamma glutamyl Cys synthetase reaction, which is subject to feedback regulation by GSH. N-acetylcysteine (NAC), a prodrug that supplies bioavailable Cys necessary for replenishment, is routinely administered to overcome pharmacologically induced GSH deficiency, for example due to acetaminophen or cyclophosphamide overdose. Other studies have suggested that NAC is an effective means for preventing or reversing the GSH deficiency in HIV infection. Similarly, Hoffer et al. incubated NAC with type II alveolar cells, and showed enhanced GSH content and prevention of paraquat-induced cytotoxicity.

In clinical practice, glutathione and NAC are two of the most commonly used antioxidants in intravenous administration.

Unfortunately, there is no practical guideline outlining how much of such antioxidant should be prescribed to facilitate the rapid increase in the antioxidant capacity of the patient in an urgent situation like paraquat intoxication. However, despite frequent use and the considerable amount of clinical knowledge on NAC, many questions remain, especially about its optimal dose.

Although Cys is a critical amino acid in the synthesis of GSH, it is very reactive in circulation and most Cys is oxidized immediately to cystine (Cys2) when it is administered intravenously.

Recently we found that extracellular methionine (Met) is as strong an antioxidant as Cys against the intracellular ROS produced by paraquat. In humans, this essential sulfur-containing amino acid is metabolized in the trans sulfuration pathway: it is successively converted to S adenosyl methionine, S adenosyl homocysteine, and homocysteine. Homocysteine lies at a branch point from which sulfur metabolism can be controlled: it can either be remethylated to Met or converted to Cys via cystathionine. The remethylation of homocysteine is catalyzed by betaine homocysteine methyltransferase and 5 methyltetrahydro folate homocysteine methyltransferase. In this setting, Cys2 has been shown to increase the activity of betaine homocysteine methyltransferase. Accordingly, one of the potential functions of extracellular NAC is as a source of both Cys and Met in the overall sulfur-containing amino acid balance. Therefore, it seems reasonable that practical guidelines for NAC dosage should be derived from pharmacokinetic studies of sulfur-containing amino acids synchronized with the changes in NAC following intravenous administration of NAC.

In light of the antioxidant effect of both Cys and Met, and the metabolic interrelationships between Met, Cys, and Cys2, we hypothesized it would be more accurate to estimate the antioxidant effect of NAC based on the change in plasma concentrations of each sulfur-containing amino acid.

The purpose of this study was to observe changes in GSH, Cys, Cys2, and Met following intravenous administration of NAC to determine the adequate loading and maintenance doses of NAC for patients suffering from acute ROS-induced injury.

MATERIALS AND METHODS

Study design
This study is composed of three parts. The first is an in vitro examination using Swiss 3T3 fibroblasts to determine the concentration of extracellular NAC, Cys, Cyst2, and Met at which more than 50% of the intracellular ROS raised by paraquat is suppressed. The second part is a pharmacokinetic study performed on humans to set the loading and maintenance doses of reduced NAC. The third part is to observe changes in plasma concentration of GSH, Cys, Cys2, and Met, following intravenous administration of NAC.

An Investigational Review Board at Soonchunhyang Chunan Hospital approved this experimental study. All subjects provided written informed consents, and participation was voluntary. All reagents were obtained from SIGMA Chemical (St. Louis, Missouri, USA) unless otherwise stated.

Measurement of Intracellular ROS
Intracellular ROS was measured at a paraquat concentration of 500 μM after an incubation period of 40 minutes at various concentrations of NAC, Cys, and Cys2. For the last 5 minutes of the stimulation, 5 μM of H2DCFDA (dichlorofluorescein diacetate) was added to measure intracellular ROS. The amount of intracellular ROS was measured following the procedures outlined by Koo et al. Cultured cells on round cover slips were stabilized in a serum-free medium without phenol red for a minimum of 30 minutes and then stimulated with paraquat for varying periods of time. ROS generation in cells was assessed using a DCF probe (2–7 dichlorofluorescein). During the last 5 minutes of stimulation, the membrane permeable diacetate form of the dye was added to the perfusate at a final concentration of 5 μM. Within the cell, esterases cleave the acetate groups from DCF diacetate, thus trapping the reduced probe intracellularly. ROS in the cells oxidize DCF, yielding a fluorescent product DCF.

Intensity values are reported based on initial values, after
subtracting background values. The cells were then immediately observed by a laser scanning confocal microscope (LSM410, Carl Zeiss). The samples were excited by a 488 nm Ar laser and images were filtered by a long pass 515 nm filter.

In our preliminary study, paraquat produced ROS in Swiss 3T3 between 50–500 μM with a dose dependent pattern at 30–60 minutes. The cells remained alive in a paraquat concentration of less than 500 μM. However, they detached within 30 minutes in a paraquat concentration of over 600 μM. Therefore, we selected the optimal condition for our experiments to be 500 μM for 30 minutes.

Blood sampling for Pharmacokinetics of NAC

Seven volunteers were participating in the pharmacokinetic study of NAC. They were medical students aged 22 and 23 years. Their mean body weight was approximately 60 kg. Subjects ate a regular diet without alcohol or any kinds of drugs including vitamins, for more than 3 days prior to the study. An indwelling intravenous catheter was placed into an antecubital vein and 25mg/kg of NAC (N-acetylcysteine, Korea United Pharm. INC., Seoul Korea) was infused in 10 min. Blood samples were obtained just prior to the infusion of NAC (basal) and at 10 min, 20 min, 30 min, 60 min, 120 min, 180 min, 360 min, and 720 min, following the bolus intravenous administration of NAC. Plasma was separated in a tube containing ethylenediamine tetraacetic acid and stored in -70°C until assay.

The pharmacokinetics of NAC were characterized by peak plasma concentration (Cmax), time to Cmax (tmax), elimination of half life (t1/2), and the area under the plasma concentration time curve (AUC). The elimination rate constant (ke) was determined by linear regression analysis of the log linear part of the concentration curve. The t1/2 was calculated by the equation $t_{1/2}=\ln(2)/K_e$. The AUC was calculated by the linear trapezoidal rule for the plasma concentration-time curve. All areas were calculated over the first 12 h and, when necessary, extrapolated to infinity. The area under the first moment of the concentration-time curve (AUMC), defined as the area under the curve of the product at time t and plasma concentration Cp, was calculated as AUMC/AUC. Total body clearance (CL) after intravenous administration was calculated as dose divided by AUC.

Loading dose=desired plasma level x volume of distribution at steady state, infusion rate=desired plasma level x clearance (volume/unit time).
Figure 1. Our preliminary study found that Swiss 3T3 fibroblasts displayed good reproducibility in both the production and the suppression of ROS, by paraquat and by antioxidants respectively. NAC at concentrations of 10~40 mM suppressed ROS in a dose-dependent manner, while 50% suppression was achieved by 10 mM NAC.

Figure 2. Effect of Cys, Cys2, and Met on the intensity of ROS in Swiss 3T3 fibroblasts. Intensity of ROS was measured by a laser scanning confocal microscope. Y axis is intensity values folds of control value. Cys, Cys2, and Met were observed to suppress ROS at various concentrations in a dose-dependent manner: both Cys and Met at 1~1000 μM, and Cys2 at 40~400 μM. 50% suppression was achieved by 10 μM of Cys and Met, and by 400 μM of Cys2.

Statistical analysis:
Results are expressed as mean±SD unless otherwise stated. Analysis of variance was used to detect differences in the concentration of NAC, Cys, Cys2, Met, and GSH among the sample groups obtained at indicated sampling times. If significant differences were shown in the overall analysis of variance models, subsequent multiple comparison testing (eg, Duncan) was performed. Statistical significance was defined as p<0.05.

RESULTS

In Vitro
Effect of NAC, Cys and Cys2 on the production of ROS by PQ in Swiss 3T3:
10~40 mM of NAC suppressed ROS in a dose dependant manner after an incubation period of 40 min at various concentration of NAC, Cys, and Cys2 at a paraquat concentration of 500 μM. 10 mM of NAC suppressed about 50% of ROS and was comparable with 10 μM of Cys and Met and 400 μM of Cys2 (Figure 1, 2).
Table 1. Mean concentration of amino acids and glutathione (µM /L) following intravenous administration of 25 mg/kg of NAC

| Amino acid | basal  | 10 min | 20 min | 30 min | 60 min | 120 min | 180 min | 360 min | 720 min |
|------------|--------|--------|--------|--------|--------|---------|---------|---------|---------|
| Cys        | 3.6 (1.9) | 3.9 (2.8) | 3.8 (1.8) | 3.6 (0.9) | 3.7 (1.0) | 3.9 (2.3) | 3.3 (2.2) | 2.6 (1.1) | 3.4 (1.8) |
| Cys2       | 2.7 (0.8) | 2.5 (0.7) | 2.6 (1.8) | 2.2 (1.5) | 1.4* (0.8) | 1.1* (0.5) | 1.3* (0.6) | 1.7 (0.6) | 2.4 (1.2) |
| Met        | 27.6 (10.7) | 24.6 (6.9) | 24.5 (10.5) | 24.8 (7.6) | 25.7 (7.5) | 26.8 (8.8) | 28.3 (6.2) | 28.9 (8.2) | 30.3 (11.5) |
| Glutathione | 7.9 (1.4) | 7.4 (0.9) | 7.3 (1.1) | 7.3 (1.5) | 7.2 (1.2) | 6.7 (1.1) | 7.0 (1.1) | 6.7 (1.5) | 7.4 (0.9) |
| total      |        |        |        |        |        |         |         |         |         |
| reduced    | 2.0 (0.8) | 1.8 (0.7) | 1.9 (1.1) | 1.9 (0.7) | 1.0 (0.8) | 1.1 (0.9) | 1.6 (0.5) | 1.8 (1.0) | 2.0 (0.9) |
| oxidised   | 5.9 (1.6) | 5.8 (1.4) | 5.4 (1.4) | 5.3 (1.7) | 5.0 (1.5) | 4.6 (1.1) | 4.5 (1.0) | 4.9 (0.9) | 5.3 (0.7) |
| NAC        | 0.9 (1.3) | 141.5 (27.7) | 86.9 (41.9) | 51.3 (22.7) | 25.7 (12.6) | 11.3 (7.8) | 8.5 (6.4) | 5.2 (5.6) | 1.8 (2.6) |
| Total NAC  | 2.8 (2.5) | 406.1 (91.8) | 183.8 (39.0) | 122.9 (36.3) | 44.5 (13.0) | 23.4 (5.9) | 17.2 (2.01) | 10.3 (2.7) | 5.4 (2.7) |

SD, standard deviation; *cystine concentrations were lower than basal level (p<0.05).

Figure 3. Plasma concentration of reduced NAC and total NAC following intravenous administration of 25 mg/kg in seven healthy volunteers. The t1/2 was 2.88±1.14 h for NAC and 3.68±1.84 h for total NAC. The CL was 1.23±0.77 L h⁻¹ kg⁻¹ for NAC and 0.56±0.27 L h⁻¹ kg⁻¹ for total NAC. The Vss was 3.07±0.10 L kg⁻¹ for NAC and 3.00±0.11 L kg⁻¹ for total NAC. Total NAC is the sum of the reduced NAC and oxidized NAC. The mean plasma concentration of NAC versus time following intravenous administration of NAC is shown in Figure 3. Briefly, basal plasma concentrations of reduced NAC was 0.9±1.3 µM and 2.8±2.5 µM for total NAC. Peak plasma concentration was 141.5±27.7 µM for NAC and 406.1±91.8 µM for total NAC, achieved 10 min following the infusion of NAC. Semilogarithmic plots of the concentration vs. time after subtracting the basal concentration showed a monoeponential decline. Therefore, the kinetics were considered to follow a first-order one compartment model.

The t1/2 was 2.88±1.14 h for NAC and 3.68±1.84 h for total NAC. The CL was 1.23±0.77 L h⁻¹ kg⁻¹ for NAC and 0.56±0.27 L h⁻¹ kg⁻¹ for total NAC.

The Vss was 3.07±0.10 L kg⁻¹ for NAC and 3.00±0.11 L kg⁻¹ for total NAC.

If the target concentration of NAC in plasma is 10 mM, the loading and maintenance doses were 5010 mg kg⁻¹ and 2250 mg min⁻¹ kg⁻¹, respectively.

DISCUSSION

Acute paraquat intoxication causes a rapid progression of ROS injuries and as a result, leads to death within a few days in most patients. In cases such as this, intravenous administration of antioxidants is the key step in early therapy, with NAC being one of the most commonly used antioxidants. Nevertheless, there are no practical guidelines relating to the adequate dose of NAC to cure acute ROS injuries.

Various methods can be used to evaluate the clinical effect of NAC, and yet the ultimate focus of studies should be placed on whether NAC can improve the critical situation of these patients. Most importantly, determining the optimum dose of NAC should therefore be the prerequisite in evaluating any antioxidants’ effect. In general, the optimum dose is a function of the effective plasma concentration and pharmacokinetic data such as clearance,
half-life, and volume of distribution for any given drug.

The effective concentration is usually defined as a range rather than a specific number and it may be described as a concentration of minimal effective, 50% suppression, and complete suppression of ROS. In our preliminary study, the requirement of NAC for complete suppression was too high to administer intravenously. Therefore we chose the target NAC concentration to be the concentration at which 50% suppression of ROS could be achieved.

This report showed that 10 mM of extracellular NAC suppresses about 50% of intracellular ROS brought about by paraquat, compared with 10 μM of Cys and Met, and 400 μM of Cys2. This suggests that Cys is a 40 times stronger antioxidant than Cys2 in an in vitro experiment, and that NAC itself is not an essential antioxidant until it is deacylated and converted to other sulfur compounds. NAC showed a half-life of 1.68 h, which was shorter than the reported value of 1.95 h32; the volume of distribution was higher (3.48 vs. 0.59 l kg⁻¹) than that in the previous report20 where relatively small doses of NAC (1500 mg vs. 200 mg) were used.

NAC has quite different metabolism systems in vitro and in vivo. It is not clear whether the results from the in vitro experiments can be applied to the in vivo experiments. However, the pharmacokinetic study showed that to reach the target concentration of 10 mM, the loading and maintenance doses of NAC were 5010 mg kg⁻¹ and 2250 mg min⁻¹ kg⁻¹, respectively. Clinically, it is impossible to give such a large dose of NAC intravenously. In our experiences, patients felt a burning sensation at the injection site when the intravenous NAC dose was over 6.0 g per hour. Furthermore, there is no clinical information that guarantees a patient’s safety when such a large volume of NAC is administered intravenously.

NAC was deemed to be an effective antioxidant in treating critical ROS injuries, but to pinpoint the optimum dosage of NAC may be controversial. It is however probable that the optimum dosage of NAC is the upper margin of the therapeutic window.

Theoretically there are various ways to calculate the effective dose of NAC. First, as was described earlier, it is the volume of distribution and/or clearance of NAC in circulation with an effective concentration that would in large part decide the optimum dose. In this experiment, NAC immediately disappeared from circulation after the intravenous administration. This result implies a rapid metabolism of both NAC and Cys caused by deacetylation, further metabolism, and movement into other compartment including intracellular space.

An assessment of the effect of an antioxidant in vivo is complicated because thiol antioxidants have been known to act in a variety of ways, as components of the general thiol/disulfide redox buffer, as metal chelators, as radical quenchers, as substrates for specific redox reactions, and as specific reductants of individual protein disulfate bonds.

The composition and redox status of the available thiols in a given compartment are highly variable and they must play a part in determining the metabolic activity of each compartment. Changes in the thiol redox gradient across the cells could also adversely affect any transport or cell signaling processes, which are dependent on the formation and the rupture of disulfide linkages in membrane proteins.

In this study, we put our test results in numbers for both in vitro and in vivo experiments, but they need to be better understood as specific values whose scale we set arbitrarily in our study alone rather than generally applicable values. Likewise, the metabolites of NAC, such as Cys, Cys2, and other sulfur compounds would provide powerful information if we could comprehend their precise metabolic processes. However, we only observed the epiphenomena of sulfur containing amino acid without an intensive study of the metabolism of each amino acid. With such limitations in this study, we conclude that there was no significant increase in the concentrations of Cys, Met and GSH after the infusion of NAC. The concentration of Cys2 decreases 60 min after the NAC administration. This finding implies that NAC reacts with, and leads to the conformational transition of Cys2.

In conclusion, our results showed that the effect of NAC as an antioxidant could not be measured in terms of the NAC plasma concentration or its metabolites alone. In order to determine the optimum dosage of NAC, other methods must be established. One consideration to be investigated is measuring intracellular GSH synthesis before and after NAC administration.

REFERENCES

1) Meister A, Anderson ME. Glutathione. Annu Rev Biochem 52:711-760, 1983

2) Han J, Cheng FC, Yang Z, Dryhurst G. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson’s disease. J Neurochem 73:1683-1695, 1999

3) Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity: implications for Parkinson’s disease. J Biol Chem 275:26096-26101, 2000

4) Jahoor F, Jackson A, Gazzard B, Phillips G, Sharpstone D, Frazer ME, Heird W. Erythrocyte glutathione deficiency in symptom free HIV infection is associated with decreased synthesis rate. Am J Physiol 276:E205-E211, 1999

5) Marray SP, Clark YM, Ness GM, Minshaw OM, Pei P, Hohl CM. Thiol redox modulation of doxorubicin mediated cytotoxicity in cultured AIDS-related Kaposi’s sarcoma cells. J Cell Biochem
9) Hagen TM, Brown LA, Jones DP. Activity of antioxidant enzymes in children at high risk of premature coronary heart disease. Scand J Clin Lab Invest 63:151–158, 2003

7) Weinbrenner T, Ciadellas M, Isabel Covas M, Fito M, Tomas M, Sentí M, Bruguera J, Marmugat J. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis 168:99–106, 2003

8) Brown LA, Bai C, Jones DP. Glutathione protection in alveolar type II cells from fetal and neonatal rabbits. Am. J Physiol 262:L305-L312, 1992

9) Hagen TM, Brown LA, Jones DP. Protection against paraquat-induced injury by exogenous GSH in pulmonary alveolar type II cells. Biochem Pharmacol 35:4337–4542, 1986

10) Bus JS, Cagen SZ, Olgaard M, Gibson JE. A mechanism of paraquat toxicity in mice and rats. Toxicol Appl Pharmacol 39:501–513, 1976

11) Reed DJ, Ellis WW, Meck RA. The inhibition of gamma glutamyl transpeptidase and glutathione isolated metabolism of rat kidney cells by L-(alpha S, 5S)-alpha-amino-3-chloro-4'-5'-difhydro-5'-isoxazololeacetic acid (AT-125: NSC-163301). Biochem Biophys Res Commun 94:1273–1277, 1980

12) Jurima-Romet M, Shek PN. Lung uptake of liposome-entrapped glutathione after intrastructural administration. J Pharm Pharmacol 43:6–10, 1991

13) Smith LJ, Anderson J, Shamsuddin M. Glutathione localization and distribution after intrastructural instillation. Am Rev Respir Dis 145:153–159, 1992

14) Taniguchi M, Hirayama K, Yamaguchi K, Tateishi N, Suzuki M. Nutritional aspects of glutathionine metabolism and function. In: Dophipline D, Poullon R, Avramovic O, eds. Glutathione: chemical, biochemical and medical aspects. p. 645–727, New York, John Wiley and Sons, 1989

15) Huang CS, Anderson ME, Meister A. Amino acid sequence and function of the light subunit of rat kidney gamma glutamylcysteine synthetase. J Biol Chem 268:2578–2583, 1993

16) Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma glutamylcysteine synthetase. J Biol Chem 268:19675–19680, 1993

17) Ferret PJ, Hammoud R, Tulliez M, Tran A, Trebden H, Jaffrey P, Malassagne B, Calmus Y, Weill B, Batteux F. Detoxification of reactive oxygen species by a nonpeptidyl mimic of superoxide dismutase cures acetaminophen-induced acute liver failure in the mouse. Hepatology 33:1173–1180, 2001

18) Harris E, Levy L, Levy J. Inhibition of cytosphosphamide (CPA) induced bladder toxicity by N-acetylcycteine (NAC) in rats. Proc West Pharmacol Soc 18:354–357, 1975

19) Fernandez PC, Machado J Jr, Heussler VT, Botteron C, Palmer GH, Dobbelaeere DA. The inhibition of N-ω-kappaB activation pathways and the induction of apoptosis by dithiocarbamates in T cells are blocked by the glutathione precursor N-acetyl-L-cysteine. Biochem Biophys Res Commun 380:1383–1394, 1999

20) de Rosa SC, Zaretsky MD, Dubs JG, Roderer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjoie I, Derensinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA, Herzenberg LA. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 30:915–929, 2000

21) Hoffier E, Shenker L, Baum Y, Tabak A. Paraquat-induced formation of leukothione B4 in rat lungs: modulation by N-acetylcysteine. Free Radic Biol Med 22:567–572, 1997

22) Mudd SH, Levy JL. Disorders of transsphalpervation. In: Stanbury JB, ed. Metabolic bases of inherited disease. 5th ed. p. 522–559, New York, McGraw-Hill, 1982

23) Young VR, Wagner DA, Burini R, Storch KJ. Methionine kinetics and balance at the 1985 FAO/WHO/UNU intake requirement in adult men studied with L-[25S-methyl-1-13C] methionine as a tracer. Am J Clin Nutr 54:377–385, 1991

24) Storch KJ, Wagner DA, Burke JF, Young VR. [1-13C-methyl-2H3]methionine kinetics in humans: methionine conservation and cystine sparing. Am J Physiol 288:E790-E798, 1990

25) Sipanuk MH, Benevenga NJ. Effect of cysteine on the metabolism of methionine in rats. J Nutr 107:1455–1467, 1977

26) Koo HY, Shin I, Lee ZW, Lee SH, Kim SH, Lee CH, Kang HS, Ha KS. Roles of RhoA and phospholipase A2 in the elevation of intracellular H2O2 by transforming growth factor-β in Swiss 373 fibroblasts. Cell Signal 11:677–683, 1999

27) Tarr GE. Methods of protein microcharacterization. In: Shively JE. ed. pp. 155–194, Clifton, NJ. Humana Press, 1986

28) Olsson B, Johannsson M, Gabrielson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34:77–82, 1988

29) Johannsson M, Westerlund D. Determination of N-acetylcysteine, intact and oxidized in plasma by column liquid chromatography and post-column derivatization. J Chromatogr 385:343–356, 1987

30) Cereser C, Guichard C, Drai J, Bannier E, Garcia I, Boget S, Parvaz P, Revol A. Quantification of reduced and total glutathione at the femtomole level by high-performance liquid chromatography with fluorescence detection: application to red blood cells and cultured fibroblasts. J Chromatogr B Biomed Sci Appl 752:123–132, 2001

31) Neuschwander-Tetri BA, Roll FJ. Glutathione measurement by high-performance liquid chromatography separation and fluorometric detection of the glutathione–orthophthalaldehyde adduct. Anal Biochem 179:236–241, 1989

32) Olsson B, Johannsson M, Gabrielson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34:77–82, 1988

33) Sagrista ML, Garcia AE, Africa de Madariaga M, Mora M. Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-L-cysteine and glutathione against free radical induced lipid peroxidation. Free Radic Res 36:229–340, 2002

34) Visseren FL, Verkerk MS, van der Bruggen T, Man J, van Asbeck RS, de Piersloot RJ. Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. Eur J Clin Invest 32(Suppl 1):84–90, 2002

35) Bistby RH, Johnson SA, Parker AW. Quenching of reactive oxidative species by protox and comparison with other antioxidants. Free Radic Biol Med 20:411–420, 1996

36) Bitbeau B, Labarre J, Toledano MB. ATP-dependent reduction of cysteine–sulphonic acid by S. cerevisiae sulphiredoxin. Nature 425:980–984, 2003

37) Das KC, Das CK. Thioredoxin: a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochem Biophys Res Commun 277:443–447, 2000